Drug intelligence / Profile preview

recombinant human coagulation factor VIII adenovirus

Development stage: Preclinical
Lead developer: Nanyue Bio
Modality: Gene Therapies
Administration: Injection

Overview

Recombinant human coagulation factor VIII adenovirus is a preclinical gene therapy candidate developed by Nanyue Bio for the treatment of Hemophilia A. The therapy utilizes an adenoviral vector to deliver the genetic sequence encoding human coagulation factor VIII (FVIII) into the patient's cells. By facilitating the endogenous expression of FVIII, the treatment aims to restore the blood's ability to clot and provide a long-term therapeutic effect, potentially reducing or eliminating the requirement for regular exogenous factor replacement infusions.

Other names: 重组人凝血因子Ⅷ腺病毒注射液Recombinant factor VIII (adenoviral vector)

Targets

F7 (Coagulation Factor VII)F10 (Factor Xa)

Beyond the preview

Go deeper on recombinant human coagulation factor VIII adenovirus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant human coagulation factor VIII adenovirus.

Explore the full profile